Main variables;No. of employees;Total
No. of companies carrying out R&D in Biotechnology;Fewer than 250 employees;972
No. of companies carrying out R&D in Biotechnology;250 or more employees;69
No. of companies carrying out R&D in Biotechnology;Total;1,041
%Companies according to biotechnology used: Genetic code;Fewer than 250 employees;33
%Companies according to biotechnology used: Genetic code;250 or more employees;45
%Companies according to biotechnology used: Genetic code;Total;34
%Companies according to biotechnology used: Functional units;Fewer than 250 employees;44
%Companies according to biotechnology used: Functional units;250 or more employees;56
%Companies according to biotechnology used: Functional units;Total;45
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Fewer than 250 employees;30
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;250 or more employees;43
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total;31
%Companies according to biotechnology used: Bioprocesses;Fewer than 250 employees;52
%Companies according to biotechnology used: Bioprocesses;250 or more employees;74
%Companies according to biotechnology used: Bioprocesses;Total;53
%Companies according to biotechnology used: Sub-cellular organisms;Fewer than 250 employees;10
%Companies according to biotechnology used: Sub-cellular organisms;250 or more employees;17
%Companies according to biotechnology used: Sub-cellular organisms;Total;10
%Companies according to biotechnology used: Bio-computing;Fewer than 250 employees;21
%Companies according to biotechnology used: Bio-computing;250 or more employees;29
%Companies according to biotechnology used: Bio-computing;Total;21
%Companies according to biotechnology used: Nanobiotechnology;Fewer than 250 employees;11
%Companies according to biotechnology used: Nanobiotechnology;250 or more employees;13
%Companies according to biotechnology used: Nanobiotechnology;Total;11
%Companies according to biotechnology used: Other;Fewer than 250 employees;14
%Companies according to biotechnology used: Other;250 or more employees;9
%Companies according to biotechnology used: Other;Total;14
Companies in which biotechnology activities are: Main and/or exclusive;Fewer than 250 employees;504
Companies in which biotechnology activities are: Main and/or exclusive;250 or more employees;20
Companies in which biotechnology activities are: Main and/or exclusive;Total;524
Companies in which biotechnology activities are: A secondary line of business;Fewer than 250 employees;177
Companies in which biotechnology activities are: A secondary line of business;250 or more employees;21
Companies in which biotechnology activities are: A secondary line of business;Total;198
Companies in which biotechnology activities are: A tool necessary for production;Fewer than 250 employees;291
Companies in which biotechnology activities are: A tool necessary for production;250 or more employees;28
Companies in which biotechnology activities are: A tool necessary for production;Total;319
%Company by field(s) of ultimate application of biotechnology use: Human Health;Fewer than 250 employees;45
%Company by field(s) of ultimate application of biotechnology use: Human Health;250 or more employees;58
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total;46
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Fewer than 250 employees;21
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;250 or more employees;9
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total;20
%Company by field(s) of ultimate application of biotechnology use: Food products;Fewer than 250 employees;36
%Company by field(s) of ultimate application of biotechnology use: Food products;250 or more employees;33
%Company by field(s) of ultimate application of biotechnology use: Food products;Total;36
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Fewer than 250 employees;24
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;250 or more employees;12
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total;23
%Company by field(s) of ultimate application of biotechnology use: Environment;Fewer than 250 employees;17
%Company by field(s) of ultimate application of biotechnology use: Environment;250 or more employees;20
%Company by field(s) of ultimate application of biotechnology use: Environment;Total;17
%Company by field(s) of ultimate application of biotechnology use: Industry;Fewer than 250 employees;16
%Company by field(s) of ultimate application of biotechnology use: Industry;250 or more employees;10
%Company by field(s) of ultimate application of biotechnology use: Industry;Total;15
Personnel in R&D in biotechnology (no. of persons);Fewer than 250 employees;6,761
Personnel in R&D in biotechnology (no. of persons);250 or more employees;2,039
Personnel in R&D in biotechnology (no. of persons);Total;8,800
Personnel in R&D in biotechnology (no. of persons): Researchers;Fewer than 250 employees;3,947
Personnel in R&D in biotechnology (no. of persons): Researchers;250 or more employees;1,177
Personnel in R&D in biotechnology (no. of persons): Researchers;Total;5,124
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Fewer than 250 employees;2,813
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;250 or more employees;862
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Total;3,676
Personnel in R&D in biotechnology (no. of persons): women;Fewer than 250 employees;3,743
Personnel in R&D in biotechnology (no. of persons): women;250 or more employees;1,110
Personnel in R&D in biotechnology (no. of persons): women;Total;4,853
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Fewer than 250 employees;2,052
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;250 or more employees;596
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Total;2,648
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Fewer than 250 employees;1,691
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;250 or more employees;514
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Total;2,205
Personnel in R&D in biotechnology (FTE);Fewer than 250 employees;4,883.0
Personnel in R&D in biotechnology (FTE);250 or more employees;1,741.2
Personnel in R&D in biotechnology (FTE);Total;6,624.1
Personnel in R&D in biotechnology (FTE): Researchers;Fewer than 250 employees;2,899.9
Personnel in R&D in biotechnology (FTE): Researchers;250 or more employees;1,015.7
Personnel in R&D in biotechnology (FTE): Researchers;Total;3,915.6
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Fewer than 250 employees;1,983.1
Personnel in R&D in biotechnology (FTE): Technicians and assistants;250 or more employees;725.4
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Total;2,708.5
Personnel in R&D in biotechnology (FTE): women;Fewer than 250 employees;2,786.8
Personnel in R&D in biotechnology (FTE): women;250 or more employees;989.2
Personnel in R&D in biotechnology (FTE): women;Total;3,776.0
Personnel in R&D in biotechnology (FTE): (women) Researchers;Fewer than 250 employees;1,533.4
Personnel in R&D in biotechnology (FTE): (women) Researchers;250 or more employees;532.3
Personnel in R&D in biotechnology (FTE): (women) Researchers;Total;2,065.7
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Fewer than 250 employees;1,253.5
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;250 or more employees;456.8
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Total;1,710.3
Internal expenditure on R&D (thousands of euros);Fewer than 250 employees;383,487
Internal expenditure on R&D (thousands of euros);250 or more employees;154,397
Internal expenditure on R&D (thousands of euros);Total;537,884
1) By nature of the expense: Current expenses;Fewer than 250 employees;322,844
1) By nature of the expense: Current expenses;250 or more employees;144,698
1) By nature of the expense: Current expenses;Total;467,542
1.1) Remuneration to researchers;Fewer than 250 employees;128,525
1.1) Remuneration to researchers;250 or more employees;53,161
1.1) Remuneration to researchers;Total;181,686
1.2) Remuneration to technicians and assistants;Fewer than 250 employees;62,541
1.2) Remuneration to technicians and assistants;250 or more employees;24,354
1.2) Remuneration to technicians and assistants;Total;86,895
1.3) Other current expenses;Fewer than 250 employees;131,778
1.3) Other current expenses;250 or more employees;67,183
1.3) Other current expenses;Total;198,961
2) By nature of the expense: Capital expenses;Fewer than 250 employees;60,643
2) By nature of the expense: Capital expenses;250 or more employees;9,699
2) By nature of the expense: Capital expenses;Total;70,342
2.1) Land and buildings;Fewer than 250 employees;13,107
2.1) Land and buildings;250 or more employees;1,762
2.1) Land and buildings;Total;14,869
2.2) Equipment and instruments;Fewer than 250 employees;45,130
2.2) Equipment and instruments;250 or more employees;7,266
2.2) Equipment and instruments;Total;52,395
2.3) Acquisition of specific R&D software;Fewer than 250 employees;2,406
2.3) Acquisition of specific R&D software;250 or more employees;671
2.3) Acquisition of specific R&D software;Total;3,077
1) By origin of the funds: National funds;Fewer than 250 employees;338,058
1) By origin of the funds: National funds;250 or more employees;127,492
1) By origin of the funds: National funds;Total;465,550
1.1) Own funds;Fewer than 250 employees;219,919
1.1) Own funds;250 or more employees;95,453
1.1) Own funds;Total;315,372
1.2) From companies;Fewer than 250 employees;29,643
1.2) From companies;250 or more employees;11,517
1.2) From companies;Total;41,160
1.3) Public Administration funds;Fewer than 250 employees;83,279
1.3) Public Administration funds;250 or more employees;19,622
1.3) Public Administration funds;Total;102,901
1.4) From Universities;Fewer than 250 employees;113
1.4) From Universities;250 or more employees;.
1.4) From Universities;Total;113
1.5) From non profit private institutions;Fewer than 250 employees;5,104
1.5) From non profit private institutions;250 or more employees;900
1.5) From non profit private institutions;Total;6,004
1) By origin of the funds: Foreign funds;Fewer than 250 employees;45,429
1) By origin of the funds: Foreign funds;250 or more employees;26,905
1) By origin of the funds: Foreign funds;Total;72,333
2.1) From EU programmes;Fewer than 250 employees;8,588
2.1) From EU programmes;250 or more employees;1,243
2.1) From EU programmes;Total;9,831
2.2) Other foreign funds;Fewer than 250 employees;36,840
2.2) Other foreign funds;250 or more employees;25,662
2.2) Other foreign funds;Total;62,502
Purchase of R&D services in biotechnology (thousands of euros);Fewer than 250 employees;86,097
Purchase of R&D services in biotechnology (thousands of euros);250 or more employees;51,898
Purchase of R&D services in biotechnology (thousands of euros);Total;137,995
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Fewer than 250 employees;65,936
Purchase of R&D services in biotechnology (thousands of euros): In Spain;250 or more employees;40,215
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total;106,150
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Fewer than 250 employees;20,162
Purchase of R&D services in biotechnology (thousands of euros): Abroad;250 or more employees;11,683
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total;31,845
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Fewer than 250 employees;52
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;250 or more employees;32
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total;50
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Fewer than 250 employees;10
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;250 or more employees;7
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total;10
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Fewer than 250 employees;13
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;250 or more employees;15
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total;13
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Fewer than 250 employees;11
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;250 or more employees;13
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total;11
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Fewer than 250 employees;17
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;250 or more employees;10
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total;17
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Fewer than 250 employees;17
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;250 or more employees;9
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Total;17
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Fewer than 250 employees;16
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;250 or more employees;19
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total;17
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Fewer than 250 employees;33
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;250 or more employees;32
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total;33
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Fewer than 250 employees;49
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;250 or more employees;54
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total;50
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Fewer than 250 employees;16
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;250 or more employees;13
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total;16
% Companies that have requested biotechnology patents in Biotechnology;Fewer than 250 employees;15
% Companies that have requested biotechnology patents in Biotechnology;250 or more employees;23
% Companies that have requested biotechnology patents in Biotechnology;Total;15
Number of patents requested;Fewer than 250 employees;362
Number of patents requested;250 or more employees;59
Number of patents requested;Total;421
% Companies with income of an international origin related to biotechnological activities;Fewer than 250 employees;19.1
% Companies with income of an international origin related to biotechnological activities;250 or more employees;14.4
% Companies with income of an international origin related to biotechnological activities;Total;18.8
% Turnover representing income of an international origin related to biotechnological activities;Fewer than 250 employees;4.40
% Turnover representing income of an international origin related to biotechnological activities;250 or more employees;0.90
% Turnover representing income of an international origin related to biotechnological activities;Total;1.20
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Fewer than 250 employees;37.50
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;250 or more employees;43.30
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Total;41.40
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Fewer than 250 employees;62.50
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;250 or more employees;56.70
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Total;58.60
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Fewer than 250 employees;93.90
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;250 or more employees;99.80
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total;97.80
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Fewer than 250 employees;3.10
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 or more employees;.
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;1.00
% Income of an international origin related with activities according to the classification: Operating source abroad;Fewer than 250 employees;1.80
% Income of an international origin related with activities according to the classification: Operating source abroad;250 or more employees;0.10
% Income of an international origin related with activities according to the classification: Operating source abroad;Total;0.60
% Income of an international origin related with activities according to the classification: Other;Fewer than 250 employees;1.30
% Income of an international origin related with activities according to the classification: Other;250 or more employees;0.10
% Income of an international origin related with activities according to the classification: Other;Total;0.50